Table 2. Time to Sustained Alleviation of All Targeted Signs and Symptoms through Day 28.^*.

Variable	Nirmatrelvir–Ritonavir (N=654)	Placebo (N=634)
Mean trial follow-up — days	27.4	27.5
Mean time at risk for event — days	13.1	13.7
No. of participants with sustained alleviation (%)	477 (72.9)	470 (74.1)
Time to sustained alleviation
Median (95% CI) — days	12 (11–13)	13 (12–14)
Mean — days	13.8	14.1
P value by log-rank test	0.60

^*Sustained alleviation of all targeted signs and symptoms was considered to have occurred on the first of 4 consecutive days during which all targeted symptoms that had been scored as moderate or severe at trial entry were scored as mild or absent and all symptoms that had been scored as mild or absent at trial entry were scored as absent. The targeted symptoms were cough, shortness of breath or difficulty breathing, feeling feverish, chills or shivering, muscle or body aches, diarrhea, nausea, vomiting, headache, sore throat, and stuffy or runny nose. Efficacy end points were evaluated in the population of participants who took at least one dose of nirmatrelvir–ritonavir or placebo had at least one postbaseline visit.